New INESSS decision support tool on bendamustine - A major step forward, says Lymphoma Canada

MONTRÉAL, Dec. 10, 2015 /CNW Telbec/ - Lymphoma Canada commends the Institut national d'excellence en santé et en services sociaux (INESSS) for the November 18 publication of the new decision support tool on the use of bendamustine for treating follicular lymphoma.

Lymphoma Canada is satisfied with the recommendations included in this new tool. Bendamustine is a medication for treating follicular lymphoma, which is often an incurable form of the disease.

Next steps
Lymphoma Canada now hopes that health care facilities across Quebec will follow INESSS's recommendations on bendamustine.  
"We've taken good note of this publication's goal: to eliminate discrepancies among the province's health care facilities that prevent consistent and fair access to the treatment," said Robin Markowitz, Chief Executive Officer of Lymphoma Canada.  

Lymphoma Canada will closely monitor compliance with INESSS's recommendations to ensure fair access to bendamustine for lymphoma patients across Quebec.

About Lymphoma Canada
Lymphoma Canada is a wholly Canadian organization that empowers patients living with lymphoma and the many people affected by the disease through education, support, and research.
For more information about the decision support tool, go to http://www.inesss.qc.ca/en/publications/publications/publication/utilisation-de-la-bendamustine-pour-le-traitement-du-lymphome-folliculaire.html.

SOURCE Lymphoma Canada

Marie-Pier Côté, 418-529-3223, ext. 36, [email protected]; Michel Champoux, 514-607-5967, [email protected]